30
MAY
2019

NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO

Posted By :
Comments : Off
Follow-Up Data From The Phase I Trial Of DCVax®-Direct, and Progress Report On The Road To Unblinding The DCVax®-L Phase III GBM Trial  BETHESDA, Md., May 30, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 2, 2019 at 4:15 p.m. CDT (Chicago Time) in the Industry Expert Showcase Theater in the exhibit...
Read More
28
MAY
2019

NW Bio Announces Settlement with Cognate BioServices Resolving Past Matters and Providing for Restart of DCVax®-Direct Production

Posted By :
Comments : Off
Resolution and Reduction Of Past Billings & Pending Stock Issuances and New DCVax®-Direct Manufacturing Agreement BETHESDA, MD., May 28, 2019  Northwest Biotherapeutics (NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement agreement with Cognate BioServices, Inc., resolving past matters and providing for restart of...
Read More
26
FEB
2019

NW Bio Hires David Innes As Vice President, Investor Relations

Posted By :
Comments : Off
31 Years Managing Portfolios At Several Major Wall Street Firms, With Emphasis On Biotech BETHESDA, MD, February 26, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has hired David Innes as Vice President, Investor Relations. Innes comes to NW Bio with over 31 years of managing portfolios at major...
Read More
08
FEB
2019

NW Bio Releases Voting Results From Annual Shareholders’ Meeting

Posted By :
Comments : Off
BETHESDA, Md., February 8, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the final voting results from the Annual Shareholder Meeting held on February 2, 2019. Votes were cast by 460,778,696 (88.7%) of the total 519,729,780 shares that were issued and outstanding on the record date of December 13, 2018, and as such...
Read More
25
JAN
2019

Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

Posted By :
Comments : Off
Focus on Complexity and Variability of Solid Tumors, and How DCVax®-L Addresses Them BETHESDA, Md., January 25, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, presented at the Phacilitate Leaders World 2019 Conference in Miami, Florida. The slide deck from this presentation can be...
Read More